CAR-T cell therapy targeting MUC17 in gastric tumors
These findings support MUC17 as a promising immunotherapeutic target for gastric cancer and demonstrate how targeting glycocalyx-associated antigens can expand the range of surface proteins amenable to CAR-T cell-based therapies in solid tumors.
Authors
- A Wolff (ORCID: https://orcid.org/0009-0004-4209-4129)
- Adele Mucci (ORCID: https://orcid.org/0000-0003-1532-4414)
- Marcela V. Maus (ORCID: https://orcid.org/0000-0002-7578-0393)
- Trisha R. Berger (ORCID: https://orcid.org/0000-0003-3439-3239)
- Diego Salas‐Benito (ORCID: https://orcid.org/0000-0002-8995-1499)
- Filippo Birocchi (ORCID: https://orcid.org/0000-0002-5214-233X)
- Amanda A. Bouffard (ORCID: https://orcid.org/0009-0003-1501-4384)
- Giulia Escobar (ORCID: https://orcid.org/0000-0001-9177-0251)
- Sangwoo Park (ORCID: https://orcid.org/0000-0002-2701-3114)
- Christine Ho (ORCID: https://orcid.org/0009-0007-7122-5310)
- Christopher Kelly (ORCID: https://orcid.org/0009-0006-6220-4588)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/jitc-2025-013120
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Damon Runyon Cancer Research Foundation
- American-Italian Cancer Foundation
- Associazione Italiana per la Ricerca sul Cancro
- Sociedad Española de Oncología Médica
- CRIS Cancer Foundation
- National Institutes of Health
- Stand Up To Cancer
- National Cancer Institute